Baird Maintains Overweight on Apellis Pharmaceuticals, Raises Price Target to $70

Baird maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and raises the price target from $45 to $70.

Benzinga · 01/07/2020 14:26

Baird maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and raises the price target from $45 to $70.